证券代码：002390 证券简称：信邦制药 公告编号：2024-056 贵州信邦制药股份有限公司 2024年第三次临时股东大会决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、本次股东大会无增加、否决或修改提案的情况。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、会议通知情况 5、会议地点：贵州省贵阳市乌当区新添大道北段 83 号科开 1 号苑 15 楼会议室 6、股权登记日：2024 年 9 月 12 日 7、召开方式：现场表决与网络投票相结合的方式 8、本次股东大会的召集、召开符合《公司法》、《证券法》、 《深圳证券交易所股票上市规则》等有关法律、法规和《公司章程》 的规定，会议合法有效。 二、会议出席情况 贵州信邦制药股份有限公司（以下简称"公司"）于 2024 年 8 月 31 日 在 《 中 国 证 券 报 》 、 《 证 券 时 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）刊登了《关于召开 2024 年第三次临 时股东大会的公告》（公告编号：2024-0 ...

关于诉讼事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、案件所处的诉讼阶段：二审判决（终审判决）。 2、上市公司所处的当事人地位：被告。 证券代码：002390 证券简称：信邦制药 公告编号：2024-055 贵州信邦制药股份有限公司 3、涉案的金额：不涉及。 4、对公司本期利润或期后利润的可能影响：不会对公司本期 利润或期后利润造成直接影响。 贵州信邦制药股份有限公司（以下简称"公司"）于近日收到 贵州省黔南布依族苗族自治州中级人民法院送达的《民事判决书》 （（2024）黔 27 民终 2314 号），现就本次涉及诉讼事项的进展情 况公告如下： 一、本次诉讼的基本情况 2024 年 3 月，公司收到贵州省罗甸县人民法院《应诉通知书》 （（2024）黔 2728 民初 542 号）、《传票》及《民事起诉状》等法 律文书，该院已经受理公司股东哈尔滨誉曦创业投资有限公司（以 下简称"哈尔滨誉曦"或"誉曦公司"）诉公司决议撤销纠纷一案。 诉讼案件的基本情况等内容可参见公司于 2024 年 3 月 30 日刊登在 《中国证券报》、《证券时 ...

公 司 研 究 医 药 生 物 信邦制药 沪深300 公 司 简 评 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 [Table_Reportdate] 2024年09月05日 [Table_invest] 买入（维持） 报告原因：业绩点评 [证券分析师 Table_Authors] 杜永宏 S0630522040001 dyh@longone.com.cn 证券分析师 伍可心 S0630522120001 wkx@longone.com.cn [Table_QuotePic] -41% -34% -26% -18% -10% -3% 5% 13% 23-09 23-12 24-03 24-06 [相关研究 Table_Report] 《信邦制药（002390）：整体经营稳 健，中药饮片快速放量——公司简评 报告》 2024.04.19 | --- | --- | |--------------------------|-----------------| | | | | 收盘价 | 2024/09/05 3.13 | | 总股本 ( 万股 ) | 1 ...

Financial Performance - The company's operating revenue for the reporting period was ¥3,046,569,827.96, a decrease of 6.45% compared to the same period last year[11]. - The net profit attributable to shareholders was ¥114,879,289.31, reflecting a decline of 26.37% year-over-year[11]. - The net profit after deducting non-recurring gains and losses was ¥114,851,463.77, down 25.97% from the previous year[11]. - The net cash flow from operating activities was ¥181,185,712.37, showing a slight increase of 0.43% compared to the same period last year[11]. - The total assets at the end of the reporting period were ¥9,005,185,038.80, a decrease of 2.59% from the end of the previous year[11]. - The net assets attributable to shareholders were ¥6,786,409,049.33, down 0.96% from the previous year[11]. - The company achieved operating revenue of CNY 304,656.98 million, a decrease of 6.45% year-on-year[25]. - Net profit attributable to shareholders was CNY 11,487.93 million, down 26.37% compared to the same period last year[25]. - The medical services segment generated revenue of CNY 80,619.49 million, a decline of 12.54% year-on-year[25]. - The pharmaceutical distribution business reported revenue of CNY 243,143.59 million, a decrease of 10.02% year-on-year[25]. - The pharmaceutical manufacturing segment saw revenue increase by 18.49% year-on-year to CNY 45,760.58 million[25]. Shareholder Information - The company reported a total share capital of 1,943,851,868 shares, with a cash dividend of 0.30 RMB per 10 shares (including tax) to be distributed to shareholders[1]. - The total number of shares eligible for dividend distribution is 1,896,406,328 shares after deducting the repurchased shares[1]. - The company has a total of 47,445,540 shares in its repurchase account, which affects the dividend distribution base[1]. - The company has a total of 1,943,851,868 shares, with 47,445,540 shares in the repurchase account, leading to a base for profit distribution of 1,896,406,328 shares[47]. - The company reported a cash dividend of 56,892,189.84 yuan, with a distribution of 0.30 yuan per 10 shares (including tax) based on a total share capital of 1,896,406,328 shares after repurchase[47]. Risk Management - The report includes a detailed disclosure of potential risks and countermeasures faced by the company, which investors are advised to pay attention to[1]. - The company has not made any commitments regarding future performance or strategic plans, highlighting the need for investors to be aware of investment risks[1]. - The company faces industry risks due to increasing regulatory pressures and declining average profit margins in the pharmaceutical sector[41]. - The company is experiencing rising costs due to increases in raw material prices and labor costs, which may impact future profitability[41]. - The company faces potential risks including accounts receivable risk, financial risk, and environmental risk, which may impact future profitability[42]. - The company is actively monitoring and adjusting strategies to mitigate identified risks and ensure sustainable development[42]. Corporate Governance - The company emphasizes the importance of accurate financial reporting and has ensured that all board members attended the meeting to review the half-year report[1]. - The company appointed several new directors and executives on February 20, 2024, as part of its governance updates[45][46]. - The company held two temporary shareholder meetings and one annual shareholder meeting in 2024, with investor participation rates of 25.48%, 48.71%, and 44.56% respectively[44]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[48]. Environmental Responsibility - The company emphasizes the importance of environmental protection, which may require increased investment and affect future profitability[42]. - The company adheres to strict environmental standards, including the Chinese Medicine Pharmaceutical Industry Water Pollutants Discharge Standard (GB21906-2008) and the Boiler Air Pollutants Discharge Standard (GB13271-2014) for liquid and gas emissions[49]. - The company is committed to environmental responsibility, as evidenced by its adherence to the Medical Waste Management Regulations and the National Hazardous Waste Directory[52]. - The company has established agreements with local sewage treatment facilities to ensure proper waste management and compliance with environmental standards[49]. - The company reported an investment of 6.8 million CNY in environmental governance and protection for the first half of 2024[57]. - The company has implemented a dynamic and real-time environmental monitoring system in compliance with national and local regulations[58]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[59]. Business Operations - The company operates a "medical services+" platform model, focusing on medical services, pharmaceutical distribution, and traditional Chinese medicine manufacturing[16]. - The company has established a medical service network with 6 medical institutions and over 4,500 beds, emphasizing integrated management and resource sharing[18]. - The company has developed 10 health food products and 5 traditional Chinese medicine health products, enhancing its product portfolio in the health sector[18]. - The company aims to enhance its market share by leveraging its geographical advantages in Guizhou Province and improving supply chain services[22]. - The company plans to accelerate the development of health products and optimize existing products based on market feedback, aiming to cultivate this segment as a new growth point[22]. - The company is focusing on high-end medical equipment investments, including advanced imaging and radiation therapy systems, to enhance medical quality[22]. - The company is actively participating in public welfare activities and providing palliative care services for late-stage cancer patients, enhancing its brand influence[22]. - The company is developing a flagship hospital that integrates medical services, teaching, research, and rehabilitation to attract top medical talent[22]. - The company is pursuing strategic cooperation with Jiangsu Provincial Hospital of Traditional Chinese Medicine to establish a flagship hospital for integrated Chinese and Western medicine[22]. Financial Reporting and Compliance - The report is part of the company's compliance with the requirements of the China Securities Regulatory Commission and the Shenzhen Stock Exchange[1]. - The company operates under the legal framework of the Company Law and Securities Law of the People's Republic of China[4]. - The financial statements have been prepared based on actual transactions and in accordance with the accounting standards issued by the Ministry of Finance[141]. - The company has evaluated its ability to continue as a going concern for the next 12 months and found no significant doubts regarding its sustainability[142]. - The financial statements reflect the company's financial position, operating results, and cash flows accurately and completely[144]. Research and Development - Research and development investment increased by 29.37% to ¥2,155,422.34, indicating a focus on innovation[26]. - The company has implemented a technology innovation plan, resulting in the granting of 1 utility model patent and ongoing research projects[25]. - Research and development expenses for the first half of 2024 were CNY 300,815.51, significantly lower than CNY 659,830.30 in the same period of 2023[118]. - The company’s management has indicated a focus on enhancing research and development capabilities in the health sector[89]. Share Repurchase - The company repurchased a total of 47,445,540 shares, accounting for 2.44% of the total share capital, with a total transaction amount of RMB 199,908,800[88]. - The maximum transaction price for the repurchased shares was RMB 4.87 per share, while the minimum was RMB 3.29 per share[88]. - The company plans to use its own funds to repurchase shares for employee stock ownership plans, with a total repurchase fund not less than RMB 100 million and not exceeding RMB 200 million[88]. Legal and Compliance Issues - The company reported a total litigation amount of 16,819.65 million yuan, with a judgment amount of 13,162.20 million yuan already adjudicated[67]. - The company has formed a provision for litigation liabilities amounting to 29.29 million yuan related to ongoing litigation as a defendant[67]. - The company engaged in related party transactions, purchasing pharmaceuticals from Guizhou Guangzheng Pharmaceutical Co., amounting to 652.72 million yuan, which represents 0.29% of similar transaction amounts[68]. - The company has not reported any penalties or rectifications during the reporting period[68].

贵州信邦制药股份有限公司 2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 单位：万元 | | --- | | | | 往来方与上市公 | 上市公司 | 2024 年期初 | 2024 年半年度 | 2024 年半年度 | 2024 | 年半年度 | 2024 年半年度 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 其他关联资金往来 | 资金往来方名称 | | | | 往来累计发生金额 | 往来资金的利息 | | | | 往来形成原因 | 往来性质 | | | | 司的关联关系 | 核算的会计科目 | 往来资金余额 | | | | 偿还累计发生金额 | 期末往来资金余额 | | | | | | | | | （不含利息） | （如有） | | | | | | | 控股股东、实际控制 | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | | | 贵州卓大医药有限责任公司 | 控股子公司 | 其他应收款 | 13,000 ...

证券代码：002390 证券简称：信邦制药 公告编号：2024-051 贵州信邦制药股份有限公司 关于第九届监事会第四次会议决议的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 贵州信邦制药股份有限公司（以下简称"公司"）第九届监事会 第四次会议（以下简称"会议"）于 2024 年 8 月 29 日在贵州省贵阳 市乌当区新添大道北段 83 号科开 1 号苑 15 楼会议室以现场与通讯 相结合的方式召开。会议通知于 2024 年 8 月 19 日以邮件、电话等方 式发出，本次应出席会议的监事 3 人，实际出席会议的监事 3 人，其 中监事赖尚阳以通讯方式参加本次会议，会议由监事会主席赖尚阳主 持。本次会议的召集、召开以及表决程序均符合《公司法》等有关法 律、法规、规范性文件和《公司章程》、《监事会议事规则》的有关规 定，会议合法有效。 二、会议审议情况 经与会监事认真审议,会议以投票表决方式形成以下决议: 1、审议通过了《2024 年半年度报告及摘要》 经审核，监事会认为：董事会编制和审核《2024 年半年度报告》 及《2024 年半年度 ...

证券代码：002390 证券简称：信邦制药 公告编号：2024-050 贵州信邦制药股份有限公司 贵州信邦制药股份有限公司（以下称"公司"）第九届董事会第 四次会议（以下简称"会议"）于 2024 年 8 月 29 日在贵州省贵阳市 乌当区新添大道北段 83 号科开 1 号苑 15 楼会议室以现场与通讯相 结合的方式召开。会议通知于 2024 年 8 月 19 日以邮件、电话等方式 发出，本次应出席会议的董事 8 人，实际出席会议的董事 8 人，其中 董事安吉、刘一烽以通讯方式参加本次会议。会议由董事长安吉主持， 公司监事和高级管理人员均列席了会议。本次会议的召集、召开以及 表决程序均符合《公司法》等有关法律、法规、规范性文件和《公司 章程》、《董事会议事规则》的有关规定，会议合法有效。 二、会议审议情况 经与会董事认真审议,会议以投票表决方式形成以下决议: 1、审议通过了《2024 年半年度报告及摘要》 表决结果：8 票同意，0 票反对，0 票弃权。 内容详见同日在《中国证券报》、《证券时报》和巨潮资讯网 （http://www.cninfo.com.cn）刊登的《2024 年半年度报告摘要》（公 告编号： ...

证券代码：002390 证券简称：信邦制药 公告编号：2024-054 贵州信邦制药股份有限公司 关于召开2024年第三次临时股东大会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次： 2024 年第三次临时股东大会。 2、股东大会的召集人：第九届董事会。 贵州信邦制药股份有限公司（以下简称"公司"）于 2024 年 8 月 29 日召开的第九届董事会第四次会议以 8 票同意，0 票反对，0 票弃权审议 通过了《关于提请召开 2024 年第三次临时股东大会的议案》，董事会同意 召开 2024 年第三次临时股东大会。 3、会议召开的合法、合规性：本次股东大会的召集、召开符合《公司 法》、《证券法》、《深圳证券交易所股票上市规则》等有关法律、法规、 规范性文件和《公司章程》、《股东大会议事规则》的规定。 4、会议召开的日期和时间： 5、召开方式：现场书面投票和网络投票相结合的方式。公司将通过深 圳证券交易所交易系统和互联网投票系统向公司股东提供网络形式的投 票平台,股东可以在网络投票时间内通过上述系统行使表决权。如果 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称"公司"）于2024年8月29 日召开的第九届董事会第四次会议、第九届监事会第四次会议审议通 过了《2024年半年度利润分配预案》，本事项尚需提交公司2024年第 三次临时股东大会审议。现将有关事宜公告如下： 一、利润分配预案的基本情况 （一）利润分配预案的具体内容 证券代码：002390 证券简称：信邦制药 公告编号：2024-052 贵州信邦制药股份有限公司 关于2024年半年度利润分配预案的公告 根据公司2024年半年度财务报告（未经审计），公司2024年半年 度实现净利润151,440,259.43元，其中归属于上市公司股东的净利润 114,879,289.31 元 ； 2024 年 半 年 度 母 公 司 实 现 的 净 利 润 为 59,680,603.56元。截至2024年6月30日，公司合并报表期末可供分配 的利润 532,797,279.46 元，母公 司 报 表 可 供 分 配 的 利 润 133,780,787.23元。 依据《上市公司监管指引第3号——上市 ...

证券代码：002390 证券简称：信邦制药 公告编号：2024-049 贵州信邦制药股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称"公司"）于近日收到 公司控股股东贵州金域实业投资合伙企业（有限合伙）（以下简称 "金域实业"）的通知，获悉其将所持有的公司部分股份办理了解 除质押业务，具体情况如下： 二、股东股份累计质押情况 特此公告。 贵州信邦制药股份有限公司 董 事 会 二〇二四年八月二十九日 截至2024年8月27日，金域实业及其一致行动人安吉、安怀略所 持质押股份情况如下： 股东 名称 是否为控股 股东或第一 大股东及其 一致行动人 本次解除质 押股份数量 （股） 占其所持 股份比例 （%） 占公司总 股本比例 （%） 质押 起始日 质押 解除日 质权人 金域 实业 是 44,000,000 12.22 2.26 2024 年 5 月 28 日 2024 年 8 月 27 日 中信证券股 份有限公司 合计 44,000,000 12.22 2.26 - - - 一、股东 ...